Ameriprise Financial Inc. Has $49.03 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Ameriprise Financial Inc. decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 44.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 118,601 shares of the company's stock after selling 93,577 shares during the period. Ameriprise Financial Inc. owned 0.14% of IDEXX Laboratories worth $49,033,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Hurley Capital LLC acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at $29,000. Rialto Wealth Management LLC bought a new stake in IDEXX Laboratories in the fourth quarter worth about $30,000. Retirement Wealth Solutions LLC bought a new stake in IDEXX Laboratories in the fourth quarter worth about $31,000. Kestra Investment Management LLC acquired a new stake in IDEXX Laboratories in the 4th quarter valued at about $38,000. Finally, Itau Unibanco Holding S.A. grew its stake in shares of IDEXX Laboratories by 540.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock worth $40,000 after purchasing an additional 81 shares during the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

IDEXX Laboratories Stock Up 0.1%

IDXX stock traded up $0.29 during mid-day trading on Wednesday, hitting $509.42. The stock had a trading volume of 552,624 shares, compared to its average volume of 650,337. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $548.88. The company has a fifty day moving average of $426.36 and a 200 day moving average of $429.96. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $40.97 billion, a price-to-earnings ratio of 47.74, a PEG ratio of 3.41 and a beta of 1.52.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.03. The company had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The business's revenue was up 3.6% compared to the same quarter last year. During the same period last year, the company earned $2.71 earnings per share. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Analysts Set New Price Targets

IDXX has been the subject of several recent research reports. Stifel Nicolaus cut their target price on shares of IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating for the company in a research note on Monday, April 14th. Barclays lifted their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Piper Sandler upped their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Bank of America increased their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Finally, StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, IDEXX Laboratories has an average rating of "Moderate Buy" and an average target price of $524.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.